OrthoTrophix Reports Data Suggesting TPX-100 May Slow Knee Osteoarthritis Progression
OrthoTrophix has released data from two studies presented at ACR Convergence 2026 regarding its intra-articular candidate, TPX-100. The findings indicate a significant link between femoral bone shape (B-score) and meniscal pathology in patients with knee osteoarthritis (KOA). In placebo groups, this relationship strengthened over time, whereas in TPX-100 treated knees, the bone shape stabilized, suggesting the therapy may alter the structural progression of the disease. Additionally, the data showed that patients with more severe baseline meniscal damage experienced greater and more durable improvements in functional outcomes, such as walking and climbing stairs, when treated with TPX-100 compared to a placebo. These results suggest that TPX-100 may be particularly effective for high-burden patients and could potentially use B-score as an objective marker for structural progression.
Topics: biopharmaceuticals clinical trial data knee osteoarthritis medical research